



# Asfotase alfa (Strensiq) Injectable Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification  
503 Sunport Lane, Orlando, FL 32809

Phone: 1-866-503-0857

FAX: 1-888-267-3277

For Medicare Advantage Part B:

FAX: 1-844-268-7263

Please indicate:  Start of treatment: Start date \_\_\_\_ / \_\_\_\_ / \_\_\_\_  
 Continuation of therapy: Date of last treatment \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Precertification Requested By: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

### A. PATIENT INFORMATION

First Name:		Last Name:	
Address:		City:	State: ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	E-mail:	
Current Weight: _____ lbs or _____ kgs		Height: _____ inches or _____ cms	

### B. INSURANCE INFORMATION

Aetna Member ID #: _____	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #: _____	If yes, provide ID#: _____ Carrier Name: _____
Insured: _____	Insured: _____
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____	Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____

### C. PRESCRIBER INFORMATION

First Name:		Last Name:		(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.	
Address:		City:	State:	ZIP:	
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider E-mail:		Office Contact Name:		Phone:	
Specialty (Check one): <input type="checkbox"/> Metabolic Specialist <input type="checkbox"/> Other: _____					

### D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

<b>Place of Administration:</b> <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____	<b>Dispensing Provider/Pharmacy: Patient Selected choice</b> <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Mail Order <input type="checkbox"/> Other: _____ Name: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____
---	---

### E. PRODUCT INFORMATION

Request is for Strensiq: Dose: \_\_\_\_\_ Frequency: \_\_\_\_\_

### F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: \_\_\_\_\_ Secondary ICD Code: \_\_\_\_\_ Other ICD Code: \_\_\_\_\_

### G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

**For All Requests:**  
Please provide the patient's weight in kg: \_\_\_\_\_

Yes  No Does the patient have a documented diagnosis of hypophosphatasia (HPP)?  
 → Please indicate the type of HPP the patient has been diagnosed with and answer the corresponding questions: **(must submit records/labs with request)**

Perinatal (lethal)  
The diagnosis has been confirmed by:  Prenatal ultrasound findings  Radiographs  
Please enter date of radiograph or ultrasound: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Perinatal (benign)  
The diagnosis has been confirmed by:  Clinical course  Prenatal ultrasound exam  
Please enter date of ultrasound or describe clinical findings: \_\_\_\_\_

Infantile  
The diagnosis has been confirmed by:  Clinical course  Laboratory findings  Radiographs  
Please enter date of radiograph or describe clinical or laboratory findings: \_\_\_\_\_

Juvenile/Childhood  
The diagnosis has been confirmed by:  Clinical course  Laboratory findings  Radiographs  
Please enter date of radiograph or describe clinical or laboratory findings: \_\_\_\_\_

Other, please select:  Adult HPP  Odontohypophosphatasia  Pseudohypophosphatasia

What age is the patient's documented onset of signs/symptoms of HPP? \_\_\_\_\_

Yes  No Does the patient have documented tissue-non-specific alkaline phosphatase (TNSALP) gene mutation?  
 Yes  No Has the patient had a laboratory test indicating a serum alkaline phosphatase (ALP) level below the age-adjusted normal range?  
 → Please provide the ALP level and date obtained: \_\_\_\_\_ IU/L Date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Continued on next page



# Asfotase alfa (Strensiq) Injectable Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for Precertification Review.)

**Aetna Precertification Notification**  
503 Sunport Lane, Orlando, FL 32809  
**Phone:** 1-866-503-0857  
**FAX:** 1-888-267-3277

**For Medicare Advantage Part B:**  
**FAX:** 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

**G. CLINICAL INFORMATION (continued)** – Required clinical information must be completed in its entirety for all precertification requests.

- Yes  No Has the patient had a laboratory test indicating a plasma pyridoxal-5'-phosphate (PLP) above the upper limit of normal?  
 → Please provide the PLP level and date obtained: \_\_\_\_\_ mcg/L Date: \_\_\_\_ / \_\_\_\_ / \_\_\_\_  
 Yes  No Was the PLP level drawn while the patient was receiving pyridoxine treatment?
- Yes  No Has the patient had a baseline ophthalmologic examination?  
 → Please provide the date of the eye exam: \_\_\_\_ / \_\_\_\_ / \_\_\_\_
- Yes  No Has the patient had a baseline renal ultrasound?  
 → Please provide the date of the ultrasound: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**For Continuation Requests:**

- Yes  No Has the patient been monitored for ectopic calcifications (eye and kidneys) during treatment?  
 → Please provide the date of the patient's last ophthalmologic exam: \_\_\_\_ / \_\_\_\_ / \_\_\_\_  
 → Please provide the date of the patient's last renal ultrasound: \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Request Completed By (Signature Required):** \_\_\_\_\_ **Date:** \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.